Capricor Therapeutics – Webinar on Upcoming Clinical Trial for Cardiac Indication in Duchenne


There has been a lot of recent Duchenne research news lately.  As a community, we are glad to see a variety of research programs moving forward with positive results. This provides hope for all those that live with Duchenne and their families.

Duchenne is a complex disease and will require a variety of treatments to address all aspects of the disease from replacing the missing protein; upregulating other proteins: addressing inflammation and fibrosis; and preventing cardiac failure, the primary cause of death for those with Duchenne.

We are hosting a webinar tomorrow with Capricor Therapeutics, Inc. to discuss Capricor’s upcoming HOPE-DUCHENNE clinical trial. The HOPE-DUCHENNE trial will evaluate CAP-1002 for the first time in patients with Duchenne with significant cardiac dysfunction. CAP-1002 is Capricor’s allogeneic, cardiosphere-derived cell (CDC) therapy already in clinical development for the treatment of heart disease.

Speakers include:

  • Dr. Linda Marbán, Chief Executive Officer of Capricor Therapeutics
  • Dr. Andrew Hamer, Vice President of Medical Affairs of Capricor
  • Debra Miller, Founder and Chief Executive Officer of CureDuchenne
  • Dr. Michael Kelly, Chief Scientific Advisor for CureDuchenne

We invite participants to join the webinar on Friday, June 19, 2015 at 3:00 p.m. ET/noon PT. To join the webinar please call (844) 337-8088 and enter conference ID number 64152106. Visit here to register online.

Here are links to other recent research updates:

Akashi Reports Positive Clinical Data on HT-100

Catabasis Pharmaceuticals Initiates MoveDMD a Phase 1/2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy

Santhera Update on Pre-NDA Meeting with FDA on Raxone®/Catena® in Duchenne Muscular Dystrophy (DMD)

Capricor Announces Receipt of FDA Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy

BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Sarepta Therapeutics Announces Plans to Submit Rolling NDA for Eteplirsen following Today’s Pre-NDA Meeting with the FDA

BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping


Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.